<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04207840</url>
  </required_header>
  <id_info>
    <org_study_id>API-E004-CL-I</org_study_id>
    <nct_id>NCT04207840</nct_id>
  </id_info>
  <brief_title>Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals</brief_title>
  <official_title>Study of Drug Exposure in Systemic Circulation of Primatene Mist (0.25mg) by Oral Inhalation, Versus Epinephrine Injection (0.30mg) by Intramuscular Injection and ProAir (0.18mg) by Oral Inhalation in Healthy Individuals: A Randomized, Safety Evaluator-blind, Three-Treatment, Crossover, Fasting Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amphastar Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amphastar Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the drug exposure profile in systemic circulation of Primatene Mist by inhalation,
      versus Epinephrine by intramuscular injection, and ProAir HFA by inhalation in healthy
      adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Actual">December 23, 2019</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of Epinephrine Plasma Concentration from time 0 to 6 hours post-dose, AUC[0-6h]</measure>
    <time_frame>From 30 minutes before dose until 24 hours after dose</time_frame>
    <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. AUC[0-6h] will be calculated with the trapezoid method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of Albuterol Plasma Concentration from time 0 to 24 hours post-dose, AUC[0-24h]</measure>
    <time_frame>From 30 minutes before dose until 24 hours after dose</time_frame>
    <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. AUC[0-24h] will be calculated with the trapezoid method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of Albuterol or Epinephrine Plasma Concentration from time 0 to infinity, AUC[0-inf]</measure>
    <time_frame>From 30 minutes before dose until 24 hours after dose</time_frame>
    <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. AUC[0-inf] will be calculated with the extrapolation method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration of Albuterol or Epinephrine, C[max]</measure>
    <time_frame>From 30 minutes before dose until 24 hours after dose</time_frame>
    <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. C[max] will be obtained directly from the plot of PK curve.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time at which Maximum Plasma Concentration of Albuterol or Epinephrine is observed, t[max]</measure>
    <time_frame>From 30 minutes before dose until 24 hours after dose</time_frame>
    <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. t[max] will be obtained directly from the plot of PK curve when the maximum concentration is observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life of Albuterol or Epinephrine, T[1/2]</measure>
    <time_frame>From 30 minutes before dose until 24 hours after dose</time_frame>
    <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Epinephrine</condition>
  <condition>Albuterol</condition>
  <condition>Asthma</condition>
  <condition>Anaphylaxis</condition>
  <arm_group>
    <arm_group_label>Primatene Mist, E004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who dosed with Primatene Mist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epinephrine Injection Auto-Injector (Generic of EpiPen)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who were dosed with an Epinephrine Injection Auto-Injector.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albuterol HFA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who dosed with Albuterol HFA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Epinephrine (0.125 mg/inhalation)</intervention_name>
    <description>Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.</description>
    <arm_group_label>Primatene Mist, E004</arm_group_label>
    <other_name>Primatene Mist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Epinephrine Injection Auto-Injector (0.3mg/0.3mL)</intervention_name>
    <description>Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.</description>
    <arm_group_label>Epinephrine Injection Auto-Injector (Generic of EpiPen)</arm_group_label>
    <other_name>Generic of EpiPen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Albuterol Sulfate (0.09 mg/inhalation)</intervention_name>
    <description>Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.</description>
    <arm_group_label>Albuterol HFA</arm_group_label>
    <other_name>Albuterol HFA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Agree to participate; understand and sign informed consent;

          -  Male and female adults, aged 18 to 50 years, inclusive at Screening;

          -  Generally healthy and medically stable, with no clinically significant abnormalities
             based on physical examination and laboratory tests as determined by the Investigators;

          -  Have good venous access;

          -  Have normal resting blood pressure and normal heart rate (HR) without history of
             syncope; a subject with out of range blood pressure may be enrolled in the study at
             the discretion of the Principal Investigator;

          -  Have a body mass index (BMI) of 18.0 - 30.0 kg/m^2;

          -  Female candidates must be &gt;1 year post-menopausal or practicing a clinically
             acceptable form of birth control and confirmed by negative urine or serum pregnancy
             test at Screening;

          -  Negative HIV-Ab, HBs-Ag and HCV-Ab;

          -  Negative alcohol test (urine or breathalyzer);

          -  Negative drug screening results;

          -  Currently non-smoker; have not used any tobacco products for at least three (3) months
             prior to Screening; and

          -  Demonstrate proficiency in the use of MDI and a consistent inhalation time &gt;2.0
             seconds after training, for at least three (3) times, with a maximum of 5 attempts.

        Exclusion Criteria:

          -  Concurrent clinically significant cardiovascular, hematological, renal, neurologic,
             hepatic, endocrine, psychiatric, or malignant diseases.

          -  Known intolerance or hypersensitivity to any component of the study drugs (i.e.,
             Epinephrine, Albuterol Sulfate or any sympathomimetic drugs, HFA-134a, thymol,
             ethanol, ascorbic acid, nitric acid, and hydrochloric acid).

          -  Upper or lower respiratory tract infection, or other systemic infection within 6 weeks
             prior to Screening;

          -  Clinically significant abnormalities in the screening/baseline ECG; prolonged
             corrected QT interval (QTcF) on ECG: men &gt;450ms, women: &gt;470ms; single or multiple
             premature ventricular contractions (PVC);

          -  Abnormal thyroid function test (if TSH is out of range, refer to T3/T4 for thyroid
             function assessment);

          -  Subject has been on other investigational drug/device studies within 30 days of
             Screening Visit or planned participation in another investigational drug trial at any
             time during this trial;

          -  Women who are pregnant or lactating or planning a pregnancy during the study period;

          -  Subject has donated or lost &gt; 500 mL of blood within 3 months of Screening;

          -  Evidence of alcohol or drug abuse or dependency within 6 months prior to screening; or

          -  Use of any of the prohibited drugs without appropriate washout.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Amphastar Study Site 0035</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 19, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Anaphylaxis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Access to patient level data and supporting clinical documents may be requested by qualified researchers. Requests will be reviewed on the basis of scientific merit. Patient data will be de-identified to protect the privacy of trial patients in line with applicable laws and regulations.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

